Leukemia Clinical Trials in San Francisco

Showing 361-380 of 495 trials

Registry for Integrative Medicine Interventions Effectiveness

NCT01754038

This registry will perform prospective surveillance of participants attending collaborating Integrative Medicine clinic sites for clinical services. All decisions about medication use, treatments, visit frequency, assessment of tolerance, and other aspects of patient management will be left to the clinical providers' discretion. We will attempt to follow the participants in the PRIMIER Registry for up to 2 years. Essential data elements that capture patient-reported outcomes and measures of clinical activity will be obtained at approximately 2-month intervals for the first 6 months, then every 6 months through the end of year 2.

All Conditions of Integrative Medicine Clinic Patients

BraveNet5,069 participantsStarted Aug 2013

La Jolla, California, United States • San Francisco, California, United States • Santa Monica, California, United States +11 more locations

COMPLETEDPHASE2< 1 mile

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

NCT00818441

This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.

Carcinoma, Non-small Cell

Pfizer119 participantsStarted Mar 2009

Orange, California, United States • Orange, California, United States • Pleasant Hill, California, United States +38 more locations

Registry for Integrative Medicine Interventions Effectiveness

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Leukemia Trials in Other Cities

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Early Diagnosis of Candidiasis in Premature Infants

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Early Weight-Bearing After Lapidus Arthrodesis

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Other Conditions in San Francisco